SCHEMBL4857376

SCHEMBL4857376

Cc1ccc(CNc2nc(-c3ccccc3)nc3ccccc23)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.81
▸ KMT2A Q03164 7/20 0.81
▸ PDE5A O76074 7/20 0.81
▸ GBA1 P04062 3/20 0.81
▸ ATM Q13315 1/20 0.81
▸ LMNA P02545 7/20 0.78
▸ MAPT P10636 5/20 0.78
▸ ALDH1A1 P00352 4/20 0.70
▸ HPGD P15428 2/20 0.70
▸ KDM4E B2RXH2 1/20 0.70
▸ PTGS1 P23219 2/20 0.69
▸ TBXAS1 P24557 2/20 0.69
▸ PTGS2 P35354 2/20 0.69
▸ APP P05067 1/20 0.69
▸ HTT P42858 1/20 0.66
▸ CYP1A2 P05177 4/20 0.64
▸ CYP3A4 P08684 4/20 0.64
▸ CYP2D6 P10635 4/20 0.64
▸ CYP2C19 P33261 4/20 0.64
▸ POLB P06746 3/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12176300 0.94 MEN1 (0.81) MEN1KMT2APDE5AGBA1ATM
SCHEMBL27899411 0.92 MEN1 (0.83) MEN1KMT2APDE5AGBA1ATM
SCHEMBL13252155 0.92 PDE5A (0.83) MEN1KMT2APDE5AGBA1ATM
SCHEMBL1083763 0.90 PDE5A (1.00) MEN1KMT2APDE5AGBA1ATM
SCHEMBL27899407 0.89 LMNA (0.67) MEN1KMT2APDE5AGBA1ATM
SCHEMBL2583554 0.87 MEN1 (1.00) MEN1KMT2APDE5AGBA1ATM
SCHEMBL5138849 0.86 PDE5A (0.82) MEN1KMT2APDE5AGBA1ATM
SCHEMBL2591972 0.86 PDE5A (1.00) MEN1KMT2APDE5AGBA1ATM
SCHEMBL4864013 0.86 PDE5A (0.81) MEN1KMT2APDE5AGBA1ATM
SCHEMBL14262792 0.85 KDM1A (0.78) MEN1KMT2APDE5AGBA1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 — — US claimed
JP-2008526734-A — — 2008-07-24 — — JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 — — EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 — — WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 — — US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 — — EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MEN1 3837/4885KMT2A 1662/4885PDE5A 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback